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The role of histamine in immediate hypersensitivity has been recognized since the 
discovery of histamine. The in vitro release of histamine has been well correlated with 
in vivo allergic reactions (1, 2). Recent studies suggest that histamine may also play 
an important role in delayed hypersensitivity. 
In the allograft situation, an increase in urinary histamine excretion has been found 
at  the  time  of rejection  (3).  An  increase  in  intracellular  histamine  formation  by 
histidine  decarboxylase activity has been demonstrated  in  rat  skin aUografts when 
compared  with  that  obtained  in  rat  skin  autografts  (4).  The  possibility  that  a 
histamine release plays a role in graft rejection has been suggested because inhibition 
of histidine decarboxylase activity induces prolonged allograft survival (5). 
In  addition  to  the  effect  of histamine  in  regulating  microcirculation  and  in 
immediate hypersensitivity reactions, histamine may also modify leukocyte reactivity. 
Histamine may suppress or diminish the following: IgE-mediated release of histamine 
from mast  cells and  basophils  (6), chemotaxis of eosinophils  (7)  and  basophils  (8), 
release of lysosomal enzymes from neutrophils (9), production or release of antibodies 
from lymphocytes (10), cytotoxicity of effector T  cells (11), production of migration 
inhibitory factor (12,  13), antigen-stimulated cell proliferation (12,  13), and mitogen- 
stimulated cell proliferation (14). 
Our  work  was  carried  out  to  study  histamine  production  during  an  in  vitro 
allogeneic response using the model of mixed leukocyte culture between donor and 
recipient of  a mouse skin allografi. We report herein the discovery of  a new lymphokine 
that is produced during the allogeneic reaction and that can induce a large increase 
in histamine synthesis. This factor was termed histamine-producing cell stimulating 
factor (HCSF). 1 
* Supported by grant C.R.L. 80102  #, from Institut National de la Sant6 et de la Recherche  M6dicale, 
Paris, France. 
INSERM FRA 3 and CNRS ERA 625. 
J  Abbreviations used in  this paper: MLC, mixed leukocyte cultures; HCSF, histamine-producing cell 
stimulating factor; HBSS, Hanks' balanced saR solution; HDC, histidine decarboxylase; MHC, major 
histocompatibility  complex. 
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Materials and Methods 
Animals and Skin  Grafting.  C57BL/6 (H-2  b) and DBA/2 (H-2  a)  and A/J (H-2")  mice were 
purchased  from Centre de  Sfilection  et  d'Elevage des  Animaux de  Laboratoire du  Centre 
National de la Recherche Scientifique, Orlfians La Source,  France (C.S.E.A.L.).  The following 
congenic mice were also used: B10 (H-2b), B10D2  (H-2d), BIOBR (H-2~), B10S (H-28), B10M 
(H-2r), B 10A (H-2a), B 10A5R, B 10A2R, B 10HTT, all obtained from C.S.E.A.L. B 10AQR were 
obtained from Olac Ltd, Bicester,  England. 
Skin aUografts  were  performed according to  the  technique described by Billingham and 
Medawar (15). 
Mixed Lymphocyte Cultures.  Animals were anesthetized with ether and killed by exsanguina- 
tion. Spleens were removed, and cell suspensions were prepared by disruption with forceps. 
After washings with  Hanks' balanced salt  solution (HBSS),  spleen cells  were counted and 
adjusted to a  final concentration of 10 ×  106 viable cells/ml in minimum essential medium 
with  Earle's salts  (Flow  Laboratories, Inc., Rockville, Md.)  supplemented with  1%  sodium 
pyruvate 100 X  (Flow Laboratories, Inc.), 1% nonessential amino acid solution, 100 X  (Flow 
Laboratories, Inc.), 1% L-glutamine (Flow Laboratories, Inc.), 100 IU/ml penicillin, and  100 
#g/mi streptomycin. No serum was added.  1 vol of immunizing cell suspension plus 1 vol of 
recipient cell  suspension were  distributed in Falcon culture flasks  (Falcon Labware, Div. of 
Becton, Dickinson & Co., Oxnard, Calif.). 2 vol of each cell suspension were cultured alone as 
control. After 24, 48, or 72 h of incubation  at 37°C in 5% CO2, cell suspensions were centrifuged 
and cell-free supernates were removed and stored at -20°C. 
Histamine Determination.  Deproteinization of supernates was performed with perchloric acid 
(final concentration 0.4  N).  Histamine content was  then  measured  with  the  fluorometric 
method of Shore et al. (16) using an automated continuous flow technique. 60 samples of 100 
/~1 each were treated per hour. With this technique, a highly reproductible linear relationship 
is obtained from 0 to 5 #g/ml of histamine base. Histidine may also influence the reaction but 
to a  negligible degree because the molar fluorescence  ratio (molar fluorescence  of histamine: 
molar fluorescence of histidine) is 15,500. The reproductibility is good (~+ 5% for concentra- 
tions <2 ng/ml and from +_0.5 to 2% for greater concentrations). With this method, as little as 
100 pg/ml of histamine can be determined. 
Preparation of HCSF-containmg  Supernate.  To  eliminate histamine synthetized  during the 
mixed lymphocyte culture (MLC), supernates of secondary MLC (and control supernates) were 
dialyzed for at least  24 h against distilled water, lyophilized, resuspended in culture medium 
(as  described  above),  and  then  filtered  on  a  0.2-/~m Nuclepore  filter  (Nuclepore,  Corp., 
Pleasanton, Calif.). Such supernates were kept at -20°C before use. 
Preparation of Cells.  Spleen cells were prepared as described above for MLC. Lymph node 
cells were collected from mesenteric, inguinal, and axillary lymph nodes and disrupted in a 
Potter-Elvehjem homogenizer. Thymus cells were obtained by gently teasing the thymus with 
forceps.  Peritoneal cells were obtained by washing the peritoneal cavity of normal C57BL/6 
mice with HBSS that contained 10 IU/rnl heparin (Liquemine Roche, Paris).  Bone marrow 
cells were removed from the femurs of mice.  Blood cells were obtained after Ficoll-Hypaque 
isolation. Immediately after collection, cells were washed twice with HBSS and resuspended in 
culture medium as described above. The final concentration of cells was 20 ×  106 cells/ml for 
spleen, lymph node, and thymus; 20 X 106 or 6 ×  106 cells/ml for bone marrow cells; 5 ×  106 
cells/ml for peritoneal cells; and 1 ×  108 cells/ml for blood cells. 
Assessment of HCSF Activity.  HCSF-containing supernates were  tested  for  their ability to 
induce histamine production from spleen or bone marrow cells  by incubating 1 ml of cell 
suspension (i.e., 20 ×  106 cells) with 1 ml of these supernates for 6, 24, 48, or 72 h at 37°C in a 
5% COs atmosphere. At the end of the incubation, cell suspensions were centrifuged, and cell- 
free supernates removed and stored at -20°C until histamine determination. 
Monoclonal Anti-Mouse-Thy  1.2  Antibody.  Monoclonal anti-mouse Thy  1.2  antibody was 
obtained from Becton Dickinson & Co., Mountain View, Calif. 10 ml of spleen cells (10 ×  10  6 
cells/ml) were incubated for 30 min at 4°C with 50/Lg of purified monoclonal antibody in 50 
~1 of phosphate-buffered saline that contained 0.1% sodium azide. Mouse-absorbed guinea pig 
complement was then added. After  1 h of incubation at 37°C, cells were  washed twice with 
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phosphate-buffered saline that contained 0.1% sodium azide. The trypan blue exclusion test 
performed after monoclonal antibody treatment showed an increase in mortality from 20 to 
30% when compared with control treatment. 
Mitomycin Treatment.  Cells (10 ×  l0  s cells/ml) were incubated for 40 min at 37°C with 50 
gg/ml of mitomycin (Ametyeine 2; Laboratoire Choay, Paris) and then washed three times. 
The effect  of mitomycin was controlled by measuring [3H]thymidine incorporation. For this 
purpose, aliquots of cell suspensions were cultured in fiat-bottomed microplates (Microtest II; 
Falcon Labware, Div. of Becton, Dickinson & Co.)  containing 106 cells/well. 18 h before the 
end of the incubation they were pulsed with  1 #Ci [3H]thymidine (Commissariat ~t I'Energie 
Atomique, Saclay, France). Each determination was performed on six samples. Cells were then 
harvested by an automated sample harvester, and the amount of [3H]thymidine incorporation 
was evaluated by liquid scintillation counting. 
Determination of  Histamine Content in Cell Suspensions.  After washings, cells were resuspended in 
distilled water. The total cellular content of histamine was then determined after disruption of 
the ceils by heating aliquots of ceils to  I00°C for  I0 min, or by freezing and thawing them 
three times. 
Determination of Histamine Synthesis 
TRANSFORMATION OF LABELED HISTIDINE INTO HISTAMINE.  At the start of the cell culture, 72 
nmol (4 vCi) of L-[2-14C]histidine (Radioehemical Centre, Amersham, England) in 20 #1 of an 
aqueous solution that contained 2% ethanol was added to 20 ×  106 bone marrow cells suspended 
in 2 ml of control supernate (diluted 1:2) or 2 ml of HCSF-containing  supernate (diluted 1:2). 
The final concentration of total histidine (labeled and unlabeled) was 0.20 mmol/liter. After 48 
h of incubation with isotope at 37°C, cell suspensions were centrifuged. The cell pellets were 
solubilized with Soluene (Packard Instrument Co., Inc., Downers Grove, Ill.) and radioactivity 
was  measured.  Supernates were  lyophilized and  resuspended in 0.7  ml  of distilled water. 
Deproteinization was then performed by adding 50 mg/ml of crystallized sulfosalicylic acid. 
After centrifugation, 500 #1 of the supernate was applied to the column of a Technicon TSM 1 
analyzer (Technicon Corp., Tarrytown, N. Y.). The elution of the Technicon Chromobeads C3 
column (23.5  ×  0.5  cm)  was performed at 57.5°C with a  flow rate of 0.55  ml/min. Three 
sodium citrate-citric acid buffer solutions (0.1 mol/liter) were then used: (a) for 1 min, a pH 
3.25  buffer solution that contained 6%  (vol:vol)  ethylene glycol monomethyl ester  (Merck, 
Darmstadt, Federal Republic of Germany) and 0.5% (vohvol) 2.2-thiodiethanol, (b) for 1 rain, 
a pH 4.25 buffer solution, and (c) for 70 min, a pH 6.0 buffer solution containing  0.55 mol/liter 
NaC1. The elution was then performed by NaOH 0.4 mol/liter for 70 min. The effluent was 
separated  into fractions of 1.1  ml.  Each  fraction was  then mixed with  10 ml of dimilume 
(Packard  Instrument Co.,  Inc.)  and  radioactivity was  measured  in  a  liquid  scintillation 
spectrometer (Searle  Delta 300;  Searle Diagnostics Inc., Subsid. of G. D.  Searle & Co., Des 
Plaines, Ill.). 
10 #i of the initial solution of labeled histidine were also applied to the chromatographic 
column and  results were  corrected  by substraction of the  values obtained in this  control 
chromatography. 
DETERMINATION OF  HISTIDINE DECARBOXYLASE  ACTIVITY (HDC).  Crude HDC extracts were 
obtained by freezing and thawing three times 20  X  106 cells suspended in  l  ml of distilled 
water. The homogenates were centrifuged at 3,000 g for  I0 min at +4°C, and the supernates 
were assayed for  HDC activity according to the method of Ritchie and Levy (17) with the 
following, slight modifications: No labeled histidine was used, and the production of histamine 
was measured using an automated spectrofluorometric technique. In brief, each tube contained 
the following reagents: 20 #l 250 mM phosphate buffer (pH 6.6 or pH 7.4), 10 #1 pyridoxal-5'- 
phosphate (I0  -4 M), I0 #I L-histidine (I0  -~ M),  I0#I distilled water, and 50/st Crude histidine 
decarboxylase (HDC) extract (equivalent to l0  s cells). These reagents were combined at +4°C 
in polystyrene tubes and mixed for  10 sec with a  Vortex mixer (Vortex-Genie, Winn B. V., 
Tolbert, Holland). Reaction tubes were then incubated in a water bath at 37°C for 30, 60, 90, 
120, or 180 rain and shaken for 10 sec every 15 min. Histamine contents of crude HDC extracts 
and reagent blanks were carried through the entire procedure. 900 #l of 0.4 N perchloric acid 
was added immediately before incubation at 37°C to blank tubes (B)  and at the end of the 
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Histamine was measured in the perchloric supernate. Each sample was assayed in triplicate 
and the resulting histamine content was averaged. Enzyme activity was calculated by substract- 
ing histamine content of (B) from that of (R) and expressed as picomoles of histamine formed/ 
hour per 106 ceils. 
Characterizatwn of HCSF 
HEAT STAmLITY.  Aliquots of HCSF-containing supernate and control supernate were placed 
at room temperature or in water baths maintained at 56°C or 80°C for 10-30 rain and tested 
thereafter for the action of HCSF. 
ULVRAFU.TRATION  PROCEDURES.  Supernates were ultrafiltered through the following Amicon 
membranes: XM 300,  XM  100, XM 50 with respective molecular weight cut off of 300,000, 
100,000, and 50,000 (Amicon Corp., Scientific Sys. Div., Lexington, Mass.). 
ENZYME SENSmVlTV.  HCSF-containing supernates were incubated  for  3  h  at  37°C  with 
either  1  mg/ml  of trypsin-30-enzygel,  1  mg/ml  of chymotrypsin-enzygel, or  1  mg/ml  of 
ribonuclease-enzygel. All these fixed enzymes were purchased  from Boehringer, Mannheim, 
Federal Republic of Germany. 
All treated fractions and controls were subsequently tested for their HCSF activity on bone 
marrow cells. 
Discontinuous Density-Gradient Separation.  A  Ficoll gradient was  prepared according to  the 
method ofTak Yan Yu et al. (18), modified by Papiernik and Bach (19), and consisted of Ficoll 
400 (Pharmacia Fine Chemicals, Uppsala, Sweden) at a concentration of 10% (wt:wt), 14.6%; 
16.1%;  17.7%; 19.2% and 23% in 0.1  M  sodium phosphate buffer, pH 7.4. The density of the 
gradient was controlled by measuring the refractive index with  a  Zeiss-Abbe refractometer 
(Carl Zeiss, Inc., New York). Refractive index of each layer (1.2 ml/layer) from the top of the 
gradient  (10%) was:  1.352, 1.360,  1.363,  1.365,  1.367,  and  1.374.  Bone  marrow  cells were 
isolated as described above and suspended in culture medium. Bone marrow cells from 10 to 20 
mice were layered on the top of the FicolI gradient in 2 mI of culture medium. The gradient 
was then centrifuged for 30 rain in an  RC2  Sorvall centrifuge (DuPont  Instruments-Sorvall, 
DuPont  Co.,  Newtown,  Conn.)  at  23,500  g  at  4°C.  Layer 0  was  defined as the  interphase 
between the culture medium and  10%  Ficoll; layer  1 was defined as between  10 and  14.6% 
Ficoll with subsequent interphases numbered sequentially. Cells from each of the six layers (the 
last one is the pellet) were washed in HBSS, counted, and adjusted to the final concentration 
of 0.5 ×  106 cells/ml in culture medium. 60-80% of the cells were recovered. 
Histochemical Procedures.  Bone marrow smears were made, air dried, and stained with May- 
Griinwald Giemsa.  For intracellular histamine detection, cell smears were  treated with  1% 
ortho-phtaldialdehyde as described by Guy-Grand et at. (20).  Alcian blue and toluidine blue 
stainings were performed as described by Miller and Walshaw (21). 
Results 
Histamine Production during MLC.  As shown in Table I, a small amount of histamine 
is found in lymphocyte culture supernates. A  slight increase in histamine production 
may  be  observed  in  a  primary  MLC  after  24  h  of  culture  (mean  values  of  5 
experiments: 22.8 +  16%  of increase) and 48 h  (mean values of 12 experiments: 34.6 
±  9.1%). A  greater and more consistent increase is observed after 3 d of culture (mean 
values of four experiments: 86  ±  25.33%).  The production of histamine  is increased 
during a secondary MLC (allograft donor versus recipient). This increased production 
of histamine during the secondary MLC is detectable only after 24 h of culture (mean 
values of 5 experiments:  t64 +  53.5%), reaches its maximum at 48 h  (mean values of 
12 experiments: 259.75  "4- 33.4%), and plateaus (mean values of 4 experiments: 208.5 
±  57.5%).  At  each  corresponding  period  of incubation  the  increase  in  histamine 
production is significantly greater in secondary MLC than in primary MLC (Student's 
t test 0.01  ~  P~  0.001). 
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TABLE  I 
Histamine Production during Prima~y and Secondary M LC between C57BL/6 and D  BA  / 2 Spleen Cells 
Histamine content after incubation of 
24 h (5)*  48 h (12)  72 h (4) 
ng/ml 
Primary MLC (without  Control supernate  23.3 +  2.8  22.8 +  1.04  28.45 :t: 3 
previous allograft) 
MLC supernate  26.10 +  4.8:1:  31.9 +  3.3§  52.25 ±  7.911 
Secondary  MLC  (per-  Control supernate  28.9 ztz 2.7  33.5 ±  2.3  38.2 :t: 3.3 
formed  12 d after al- 
lograft) 
MLC supernate  73.6 +  12.8¶  L23.8 +  16.9"*  125.9 +  39.1"* 
* Number of experiments is in parenthesis. 
:]: P compared with control: not significant. 
§ P compared with control: <0.02. 
11 P compared with control: <0.05. 
¶ P compared with control: <0.01. 
** P compared with control: <0.001. 
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FIc.  1.  Increased histamine production during secondary MLC  performed at different intervals 
after grafting. Each point represents  the mean values  of nine mice.  (a)  Histamine production  is 
expressed by the following formula: 
histamine production during MLC -  histamine production during control culture 
x 100. 
histamine production during control culture 
(b) Specific stimulation: spleen cells from C57BL/6 mice grafted with DBA/2 skin cultured with 
DBA/2 cells. Nonspecific  stimulation: spleen  cells from C57BL/6 mice grafted with DBA/2 skin 
cultured with CBA cells. 
donor and recipient appears  7 d  after the graft, reaches its maximum  during allograft 
rejection  (day  10),  remains  high  until  day  20,  and  then  begin  to  decrease  (Fig.  1). 
Stimulation  of  recipient  cells  with  third-party  cells  also  induces  an  increase  in 
histamine  production,  but  to a  lesser degree. The  difference in histamine production 
between  specific and  nonspecific stimulation  is significant  (Student's  t  test  0.01  ~< P 
0.001)  (Fig.  I). 
(a)  Effect  of Monoclonal Anti-Mouse" Thy  1.2 Antibody  Treatment.  When  spleen  cells 
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1.2  antibody,  the  production  of histamine  during  MLC  is considerably  diminished 
when compared with that of MLC performed with control cells that have been treated 
with mouse-absorbed guinea pig complement but without anti-mouse Thy  1.2 anti- 
body; 71.3% of decrease in histamine production; n =  6: see Table II. 
This suggests an involvement of T  lymphocytes in the phenomenon. 
(b)  Effect  of Mitomycin  Treatment on Histamine  Production during Secondary MLC.  As 
shown in Table  III, mitomycin treatment  of donor cells does not  modify histamine 
production  during secondary MLC.  Surprisingly,  mitomycin treatment  of recipient 
cells  or  of recipient  and  immunizing  cells  does  not  abolish  histamine  production 
although  [nH]thymidine  incorporation  is  completely  abolished.  However,  such  a 
treatment  induces a  significant (P <  0.05) decrease in histamine production. 
(c)  Increase  in Histamine Production during Secondary MLC Does Not Result from an Increase 
in Histamine Secretion.  That  the  increase  in  histamine  production  during secondary 
MLC  does  not  result  from  an  increase  in  histamine  secretion  can  be  affirmed  by 
determining  histamine  content  in  supernates  and  cells  before  and  after  the  MLC. 
Results reported  in Table IV show that a  very small  amount of histamine is present 
in cells before culture. After a 48-h incubation, the total histamine content (supernate 
and  cells)  is  significantly  higher  in  secondary  MLC  than  in  controls  (C57BL/6 
cultured alone plus DBA/2 cultured alone). 
(d)  Studies on  the  Specificity of the Stimulating  Cell Inducing the Increase in  Histamine 
Production During Secondarr MLC.  To  investigate  alloantigens  coded  by  the  major 
histocompatibility  complex  (H-2)  necessary  for  the  induction  of  the  increase  in 
histamine production during secondary MLC, we used congenic mice. 
(i)  Histamine Production During Secondary MLC Performed with Third-Party Cells Differing 
TABLE II 
Histamine Production during MLC after Monoclonal Anti-Thy 1.2 Antibody Treatment 
MLC performed with 
Percentage of increase in histamine production 
Exp. 1  Exp.  2  Exp.  3  Exp. 4  Exp. 5  Exp. 6 
Control-treated cells*  338  125  283  111  215  177 
Anti-Thy 1.2-antibody-treated cells~:  84  30  92  20  63  6 
* Control-treated  ceils: cells incubated  with  mouse-absorbed guinea  pig serum without  anti-Thy  1.2 
antibody. 
~: Anti-Thy  1.2 antibody-treated  cells: cells incubated  with anti-Thy  1.2 antibody and  mouse-absorbed 
guinea pig serum. 
TABLE III 
Effect of Mitomycin Treatment on Histamine Production during Secondary MLC 
Percentage of in-  [aH]Thymidine 
Mitomycin treatment of  crease  in histamine  P 
production  incorporation 
48-h secondary MLC be- 
tween  skin allograft 
donor  and  recipient 
mice 
c  j0m 
No cells  280.6 ± 57.6  21,427 ± 3,331 
Recipient and immuniz-  121.8:1:35.8  <0.05  1,212 zlz 321 
ing cells 
Immunizing cells  292.2:1:64.8  NS*  16,095:1:593 
Recipient cells  132.6 ± 35.7  <0.1  14,593 ± 2,239 
* NS, not significant. M.  DY, B.  LEBEL P.  KAMOUN, J.  HAMBURGER 
TABLE IV 
Histamine Content in Supernate and Cells of SecondaTy MLC (a Typical  Experiment) 
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Histamine content 
Cells  Supernates  Total 
ng 
Before culture 
20 ×  106 spleen cells from DBA/2-grafted C57BL/6 mouse  6.8  4.4  11.2 
(in 2 ml) 
20 ×  106 spleen cells from normal DBA/2 (in 2 ml)  6.2  3.2  9.4 
After 48 h of culture of control (cells cultured alone) 
20 ×  108 spleen cells from DBA/2-grafied C57BL/6 mouse  6.6  65.2  71.8 
(in 2 ml) 
20 ×  106 spleen cells from normal DBA/2 (in 2 ml)  3.2  23.6  26.8 
MLC 
20 ×  10  s spleen cells from DBA/2-grafted C57BL/6 mouse 
+ 20 ×  106 spleen cells from normal DBA/2 (in 4 ml) 
25.6  460.2  485.7 
at  the  Whole 11-2 Region with  Immunizing  Cells.  Maximum  increase  in  histamine 
production is always found when recipient cells were cultured with immunizing strain 
cells. If, in each experiment,  the percentage of increase in histamine production with 
immunizing cells  is  taken  as  100%  (after substraction  of the  percentage of increase 
during  primary  MLC  with  same  ceils),  stimulation  of spleen  cells  from  allograft 
recipient  with  third-party  cells  differing at  the  whole  H-2 region  with  immunizing 
cells  induces between  3 and  23% of the response obtained  with specific stimulation 
(Table V). 
(ii)  Histamine  Production During Secondary MLC Performed with Stimulating  Cells with 
Partial Homology at the H-2 Region with Immunizing Cells.  Table VI shows that partial 
homology at the H-2 region between immunizing and stimulating cells is sufficient to 
induce an increase in histamine production during the secondary MLC. Homology at 
IC-S-G  and  D  loci  is  sufficient  (Table  VI,  combinations  2  and  3)  to  induce  the 
increase in histamine production, whereas homology at IC-S and G  loci is insufficient 
(Table VI, combination 4). Similarly, homology at IE-IC-S-G and D  loci (Table VI, 
combination 6) is also sufficient, whereas identity at IE-IC-S and G  loci (combination 
11) is insufficient. This suggest the importance of the homology at D  locus and this is 
confirmed in combination  5, where  70%  of the  response obtained  with  immunizing 
cells is obtained with a stimulating cell having only the H-2D region in common with 
donor cells. Homology at K-IA-IB-IJ and IE loci is also sufficient to obtain an increase 
in histamine production identical to that obtained with immunizing cells (Table VI, 
combination  8  and  10), but homology at  IA-IB and IJ loci  (Table VI, combination 
12)  induces only 18.5% of the maximal response. This suggests the importance of the 
homology at K  locus. 
Evidence for the Production of HCSF during Secondary MLC.  48-h  dialyzed secondary 
MLC supernates  (<2 ng/ml histamine)  were tested for their HCSF activity. Incuba- 
tion of normal spleen cells for 48 h with dialyzed supernate of mixed cultures between 
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TABLE  V 
Histamine Production in Secondary MLC Performed  with Third-Party Cells Differing at the Whole  H-2 
Region with Immunizing Cells 
Percentage of increase in histamine production* after 48 h of culture with 
spleen cells from 
B10 (H-2  b)  BIOD2 (H-2  a)  BIOBR (H-2 k)  BIOS  (H-2*)  BIOM (H-2  t) 
(8)  (8)  (8)  (4)  (3) 
Spleen cells from BI0 (H-2 b) 
mice bearing skin graft 
from 
BIOD2 (H-2  d) mouse  0  100  23.5 ± 6.5  5.3 ±  2.6  3.3 :t: 2.8 
BIOBR (H-2 ~) mouse  0  7.5 ±  2.4  100  12,8 ±  6.0  12.3 ±  4.2 
Primary MLC was performed with B10 mice bearing syngeneic skin graft.  Number of experiments is in 
parenthesis, 
* The percentage of increase in histamine production was calculated with the following formula: 
percentage of increase in histamine 
production during secondary MLC 
performed with tested cells 
percentage of increase in histamine 
production during primary MLC 
performed with tested ceils 
percentage ----  X I00. 
percentage of increase in histamine 
production during secondary MLC 
performed with immunizing cell 
percentage of increase in histamine 
production during primary MLC 
performed with immunizing cell 
TABLE VI 
Histamine Production during Secondary MLC Performed  with Stimulating Cells Bearing Partial Homology 
at the H-2 Region with Immunizing Cells 
Percentage of 
Combina-  Stimulating  H-2 homology be-  increase* in his- 
tions  Recipient  Donor  cells  tween donor and  Number of  tamine produc- 
stimulating cells  experiments  tion after 48 h 
of incubation 
1  B10  BI0D2  B10D2  Total  8  100 
2  B10  B10D2  B10A  IC-S-G-D  8  90.1 +  13.6 
3  B10  B10D2  B10A5R  IC-S-G-D  5  79.6 +  6.1 
4  B10  B10D2  B10A2R  IC-S-G  5  6 +  1.9 
5  B10  B10D2  B 10HTT  D  5  70.4:1:10.6 
6  B10  B10D2  BIOAQR  IE-IG-S-G-D  4  86.5 ± 8 
7  B10  B10BR  B10BR  Total  8  100 
8  B10  BIOBR  B10A  K-IA-IB-IJ-IE  8  97.5 ±  7.7 
9  B10  B10BR  BIOA5R  IJ-IE  5  4.2 ±  2.2 
10  B10  BIOBR  B10A2R  K-IA-IB-IJ-IE  5  106.6 ±  14.5 
11  B10  B10BR  B10HTT  IE-IC-S-G  5  6.8 ±  4 
12  B10  B10BR  B 10AQR  IA-IB-IJ  4  18.5 ±  9.1 
* Percentage of increase  in histamine production is calculated by estimating the response obtained with 
immunizing cells as 100% (see Table IV). 
when compared  with that obtained after a  48-h incubation with control supernates 
(mean values of increase percentage from 22 experiments: 170.3  -  21.7%). 
Such an effect of HCSF-containing supernate is not detected after 6 h  of incubation, 
but appears after 24  h, reaches its maximum  at  48  h, and remains at  the same level 
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HCSF activity may be detected by using spleen, bone marrow, blood, or peritoneal 
cells  as  targets  but  not  with  lymph  node  and  thymus  cells  (Table VII).  As  the 
spontaneous histamine release from peritoneal cells is higher than that of spleen or 
bone marrow cells (294.4 ±  81.1  ng/ml, 29.2 ±  5.9 ng/ml, and 117.7 :l: 20.4 ng/ml, 
respectively), the percentage increase induced by HCSF on peritoneal cells is less than 
with spleen or bone marrow cells (42.6 ±  15.4% against  170.3 ±  21.7% and 305.5 :t: 
25.6%, respectively). 
The activity is concentration dependent because it is usually lost by a 30- to 60-fold 
dilution of the supernate. 
With bone marrow or spleen cells as target cells of HCSF activity, it can be seen in 
Table VIII that the effect of HCSF is not major histocompatibility complex (MHC) 
restricted, as  HCSF obtained from  C57BL/6 mouse (H-2~  can increase histamine 
production from target cells hearing different MHC  (H-2  d,  H-2  k, or H-28). On the 
other hand, mouse HCSF cannot act on rat or guinea-pig spleen and bone marrow 
cells (Table VIII). 
TABLE VII 
HCSF-containing Supernate Effect on Histamine Production by Various Kinds of Cells 
Histamine production increase* after HCSF-containing supernate treatment 
on 107 cells from 
Peritoneal  Lymph  Thymus  Spleen  Bone  marrow  Blood  cavity  nodes 
Mean values from six ex-  89 ± 9  578 ± 76 
periments ± SEM 
ng/ml 
166 ± 31  140±61  6±3  4±2 
* Difference between histamine production after  HCSF-containing supernate and that  obtained  after 
control supernate treatment. 
TABLE VIII 
HCSF Activity is Not MHC-restricted but Cannot Induce Modification in Xenogenic 
Cells 
H-2  b HCSF activity* tested on 
Percentage of histamine increase by 
Spleen cells  Bone marrow cells 
H-2  b cells  124.4 ± 38.2  383.3 ± 53.9 
(C57BL/6 and B10) (9):[: 
H-2  a cells  118.1 ± 38.7  252.8 ± 46.1 
(DBA/2 and B10D2) (9) 
H-2  k cells  137.6 ± 28.4  272.3 ± 69.7 
(CBA and B10BR) (9) 
H-2  ~  cells  106.5 ± 9.5  324 ± 47.4 
(SJL and B 10S) (4) 
Rat cells (4)  6.25 ± 6  4.5 ± 2.5 
Guinea pig cells (2)  5 ±  1  0 
* HCSF has been obtained during secondary MLC between DBA/2- (H-2  a) grafted 
C57BL/6 (H-2~ and DBA/2 (H-2a). 
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Effect of HCSF on Bone Marrow Cells 
To study the  HCSF mechanism of action, we have chosen bone marrow cells  as 
target cells  because they are the most sensitive to HCSF (Table VII). 
EFFECT OF  HCSF  ON  HISTAMINE RELEASE.  Before  culture,  bone  marrow  cells 
contained  a  very small  amount of histamine.  Incubation with  HCSF increases  the 
total histamine content. As shown in Table IX, HCSF induces an increased histamine 
production  not  only  in  supernates  but  also  within  cells  (means  values  of  four 
experiments: 62.6 +  2.5 ng in HCSF-treated cells  instead of 17.4 +  4.1  ng in control- 
treated cells). 
EFFECT OF HCSF ON CONVERSION OF HISTIDINE  INTO HISTAMINE.  Cultures of bone 
marrow cells  were performed in the presence of 4/zCi of L-[2-I4C]histidine (i.e.,  72 
nmol). After a 48-h incubation, labeled histamine was determined in the supernate of 
bone marrow cells treated with control or HCSF-containing supernate. The results of 
a  typical experiment reported Fig. 2, clearly show that HCSF induces an increase in 
the  transformation  of labeled  histidine.  2.2%  of total  histidine  (i.e.,  10,4 nmol)  is 
transformed into histamine during HCSF treatment  instead of 0.67%  (i.e.,  3.2 nmol) 
during control treatment. 
EFFECT OF HCSF ON HISTIDINE  DECARBOXYLASE  ACTIVITY.  The increase of transfor- 
mation of histidine into histamine after HCSF treatment strongly suggests that this 
factor  acts  by  increasing  histidine  decarboxylase  (HDC)  activity.  This  has  been 
confirmed  by  determining  HDC  activity  in  the  lysate  of bone  marrow  cells  after 
control  or  HCSF-containing  supernate  treatment.  HDC  activity  was  weak,  but  a 
significant increase is induced by HCSF-containing supernate (at pH 7.4, mean values 
of six  experiments  were:  284  +  45%  of increase;  at  pH  6.6,  333  +-  179%), when 
compared with control supernate. 
Location of HCSF Target Cells After Discontinuous Ficoll Gradient Separation.  As shown 
in Table X, bone marrow cells  from layers 2 and 3 were the most sensitive to HCSF 
activity, whereas layers 0,  1, 4, 5, and 6 showed minimal stimulation. 
TABLE IX 
Histamine Content of Bone Marrow Cell Culture after HCSF Treatment 
Exp. 
Histamine content in 
Cells  Supernate  Total 
Before treatment 
20 X  106 bone marrow ceils (in 2 ml) 
1  6.2  2.6  8.8 
2  6.6  3.8  10.4 
3  5.9  4  9.9 
4  4.7  2.4  7.1 
After 48 h of control treatment 
20 ×  106 bone marrow cells (in 2 ml) 
1  29  370  399 
2  10.4  344  354A 
3  13.8  458  471.8 
4  16.5  392  408.5 
After 48 h of HCSF treatment 
20 ×  10  n bone marrow cells (in 2 ml) 
1  60.6  1,487  1,547.6 
2  57  1,180  1,237 
3  68.7  1,462  1,530.7 
4  64.3  618  682.3 0.6- 
47 
i!  L=--~- o.4- 
t,g  ~ 
~E 
~e~ 0.2. 
50  55  60 
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Fro.  2.  Histamine  formation  from  histidine  by  control  or  HCSF-treated  cells.  (C)) Histamine 
formation by HCSF-treated cells; (0) histamine formation by control-treated cells. 
TABLE  X 
Fractionation of Bone Marrow Cells by Ficoll Gradient Location of HCSF Target Cells 
Background of hista- 
Percentage of overall  mine production per 
Layers  recovered cells  10  s cells 
Mean (+ SEM) increase 
in histamine production 
per l0  s cells incubated 
with HCSF-containing 
supernate 
ng  ng 
0  0.26 +  0.03  15 +  5.4  1.2 +  0.6 
1  0.23 ::1:0.03  34:1:9  108 ::t: 20.4 
2  0.63 ::1:0.23  425 ±  71.2  1,194.6 +  278.1 
3  3.13 ±  1.08  389.6 ±  91.6  1,433.3 ±  346.5 
4  13.57 +  3.24  112.2 ±  38.8  378:1: 134.9 
5  38.85:1:3.76  33.4 5= 6  60.2 ::1:: 15.3 
6  43.43 ±  3.44  22 ±  3.8  27.2 ±  9.5 
Results  are  the  mean  values  :1:  SEM  of seven  experiments.  After HCSF treatment  the 
increase  in histamine production by 106 nonfractionated bone marrow cells in these experi- 
ments is 147.5 ±  53.2 ng. 
Morphological  observations  show  that  layers  2  and  3  contain  some cells with  an 
indented, bi-, or polylobulated nucleus, and have granules distributed  throughout  the 
cytoplasm.  The  granules  are stained  with  alcian  blue at  pH  0.3  and  toluidine  blue 
(with  metachromasy).  In  smears  treated  with  ortho-phtaldialdehyde  (intracellular 
detection of histamine),  these granules show a  yellow fluorescence. 
These features may be considered as characteristic of basophilic cells. Such cells are 
sparce, but appear to be more numerous  after HCSF-containing-supernate  treatment 
(1-3%)  when compared  with control supernate  treatment  (<0.5%). 
Physicochemical Characteristics  of HCSF.  The HCSF  activity was entirely retained  in 
supernates  incubated at 56°C for 2 h  and also at 80°C for 10 min (after eentrifugation 
to  eliminate  the  precipitate)  (Fig.  3).  Ultrafiltration  on  Amicon  filter XM  300  and 
XM  100  did  not  abolish  HCSF  activity  in  the  ultrafiltrate  (mean  values  of three 
experiments:  239  -t-  65%  and  218.7  +  20%  of increase  production  of histamine  by 
ultrafiltrate  on XM  300 or XM  100,  versus  307.2  +  24.3%  by nonfiltered supernate, 
respectively). Ultrafiltration  on Amicon  filter XM  50 retained  HCSF  activity in the 304  HISTAMINE PRODUCTION  DURING THE  ANTI-ALLOGRAFT  RESPONSE 
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FIG.  3.  Effect  of heat  treatment  (80°C  for  10  min)  on  HCSF  activity.  Mean  values  of five 
experiments +  SEM. (O)  Percent of increase in histamine production by normal bone marrow cells 
in presence of HCSF-containing supernate without heat treatment;  (0) same as above in presence 
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Fzo.  4.  Effect  of enzyme treatment on HCSF activity.  A typical experiment. The same kind of 
results have been obtained in three other experiments. 
medium  upper  filter  (174.3  +  58%  of histamine  increase  by  medium  upper  filter 
against  24 ±  2% ultrafiltrate).  As shown in Fig.  4, treatment with trypsin abolished 
HCSF activity. Chymotrypsin treatment strongly diminished HCSF activity, whereas 
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Discussion 
Many substances are produced during MLC between allograft donor and recipient. 
They include a series of lymphokines, such as the migration inhibitory factor (22) and 
the  macrophage-activating  factor  (23,  24),  and  more  common  substances  such  as 
prostaglandins  (25)  and urea and ornithine (26).  In this paper, we demonstrate that 
histamine  may  also  be  found  in  large  amounts.  Histamine  production  is  greatly 
increased during culture of allograft recipient spleen cells in the presence of immu- 
nizing cells  (secondary MLC)  as compared with that  found in primary MLC  (i.e., 
without  previous allograft sensitization).  The increase in histamine  production ob- 
served during secondary MLC  may be explained by the action of a  soluble factor 
produced during culture, because the dialyzed secondary MLC supernate is able to 
induce increased histamine production from normal spleen or bone marrow cells. We 
suggest  that  this  mediator be  termed:  histamine-producing  cell  stimulating  factor 
(HCSF). 
The HCSF-producing cells are probably T  lymphocytes because:  (a)  treatment of 
recipient spleen cells by monoclonal anti-mouse Thy-1.2 antibody strongly diminishes 
histamine production during specific MLC  and  (b)  concanavalin A  stimulation  of 
normal spleen cells induces HCSF production (M. Dy, B. Lebel, P. Kamoun, and J. 
Hamburger, manuscript in preparation). The increase in histamine production during 
secondary  MLC  requires  specific  stimulation  with  cells  bearing,  at  least  partly, 
the H-2 antigens of immunizing cells.  Partial homology at the H-2 complex between 
immunizing and stimulating cells is sufficient to induce the phenomenon. However, 
studies using recombinant congenic mice demonstrate that such an homology has to 
be coded by K and D loci. In that respect, HCSF production differs from proliferative 
responses during secondary MLC, because an increase in [3H]thymidine incorporation 
can be fully triggered by determinants coded by the I region of the H-2 complex (27, 
28). Conversely, there is an immunogenetic similarity between HCSF production and 
lymphocyte cytotoxicity: both require K- and D-coded determinant recognition (29). 
Whatever the exact subclasses oft  lymphocytes producing HCSF, our results strongly 
suggest that this factor is a lymphokine. Like other factors produced by lymphocytes, 
HCSF  is  still  produced by mitomycin-C-blocked lymphocytes and  its  effect is  not 
MHC restricted. 
Studies of the mechanism of action of HCSF on bone marrow cells demonstrate 
that  it  induces an  increase in histamine synthesis. This conclusion is based on  the 
following facts: (a) the amount of intracellular histamine of bone marrow cells before 
culture is extremely low; (b) the total histamine content (cells and supernates) is much 
greater in HCSF-treated cells than in cells treated by control supernates,  (c)  HCSF 
induces an increase in the amount of labeled histidine transformed into histamine; 
and (d) HDC activity is increased in the homogenate of HCSF-treated bone marrow 
cells when compared with that of control cells. 
Although it is clear that HCSF induces an increase in histamine synthesis, at least 
two possibilities remain open:  (a)  HCSF may act on its target cell by increasing its 
HDC activity or (b) HCSF may increase the number of cells that contain HDC. That 
mitomycin C  blocks neither the increase in histamine production during secondary 
MLC nor the effect of HCSF on bone marrow cells (M.  Dy, B.  Lebel, P. Kamoun, 
and J.  Hamburger, manuscript  in  preparation)  would suggest  that  the  increase in 
histamine production does not  result from a  proliferative response.  However, other 306  HISTAMINE PRODUCTION  DURING THE  ANTI-ALLOGRAFT RESPONSE 
data suggest that HCSF might act as a factor of maturation or even proliferation of 
precursor cells with initially low histidine decarboxylase activity. These data are:  (a) 
the target cell is clearly much more abundant  in bone marrow than in other sites; 
more  generally,  the  intensity  of the  observed  effect  is  well  correlated  with  the 
distribution  of mast  cell  precursors  in  hematopoietic and  lymphopoietic tissues  of 
mice  (30,  31)  and  (b)  fractionation of bone marrow cells on a  discontinuous Ficoll 
gradient shows that cells from layers 2 and 3 (the less-dense cells) are the most sensitive 
to HCSF. In these layers, morphological studies show the presence of cells having the 
features of immature cells with granules; these cells could be precursors of basophils 
or mastocytes. They are more numerous after HCSF supernate treatment  for 48 h, 
when compared with control treatment.  2 
Some factors produced by leukocytes and  which trigger the release of histamine 
from  basophils  have  been  described  (32-34).  These  factors  differ  from  HCSF  in 
several significant ways, including their mechanism of action (an increase in histamine 
release instead of an increase in histamine synthesis), their time-course of histamine 
production, and their apparent molecular weights. 
Recently, a factor (basophilopoietine) produced by antigenic or mitogenic lympho- 
cyte stimulation in guinea-pigs and increasing basophil production in bone-marrow 
has  been  described by  Denburg et  al.  (35).  The possible  relation  between  HCSF, 
basophilopoietine  (35)  and  others  lymphomononuclear cell-derived  factors  which 
stimulate the in vitro differentiation of bone marrow precursor cells (36-38) will have 
to be further investigated. 
In  the  allograft  situation,  the production of HCSF  may explain  the  number of 
basophils  found  among  cells  infiltrating allografts  in  the  guinea-pig  (39)  and  the 
increase of histidine decarboxylase found in skin allografts at the time of rejection (4) 
because the maximum level of HCSF production coincides with skin rejection (Fig. 
1). The local production of histamine induced by HCSF could play a double role in 
allograft rejection. First, it may contribute to the alteration in capillary permeability, 
which  is  known  to be  important  in  the  mechanism  of rejection.  Second, it  might 
interfere with the regulation of the immune process. In effect, it is well established 
now that histamine interferes with the lymphocyte response. The following hypothesis 
may be presented: Sensitized lymphocytes infiltrating the graft secrete lymphokines, 
including HCSF. This factor would act on basophil or mastocyte precursors. Hista- 
mine thus released locally stimulates suppressor T  lymphocytes that would, in turn, 
inhibit  the lymphokine production and the other steps of the lymphocyte response 
(40).  The  phenomenon  may  then  represent  a  local  feedback  immunoregulation, 
limiting the response both in duration and extent. Such an hypothesis concerning the 
allograft model can be compared with a  similar hypothesis suggested in the case of 
delayed-type hypersensitivity reactions (40). 
Summary 
Histamine  production  is  greatly  increased  during  culture  of allograft  recipient 
spleen cells in the presence of immunizing cells (secondary mixed leukocyte cultures 
[MLC]) as compared to that found in primary MLC (i.e., without previous allograft). 
2 Since this paper was written, we have also found that  long-term-culture experiments of the above- 
mentioned layers 2 and 3 in the presence of HCSF-containing supernates induce a  large proliferation of 
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This  phenomenon  appears  after  24 h  of culture  and  reaches  its  maximum  at  48  h. 
Optimal  increased  histamine  production  is observed when  MLC  is  performed with 
spleen  cells  removed  from  mice  during  rejection.  This  increased  production  of 
histamine  during  secondary  MLC  results  from  the  action  of a  lymphokine:  the 
histamine-producing  cell  stimulating  factor  (HCSF).  This  factor  is  released  by  T 
lymphocytes. Its production requires specific stimulation of the recipient lymphocytes 
because increase in histamine production during secondary MLC can be only observed 
when recipient cells are cultured with stimulating cells bearing at least one homology 
at  K  or D  loci with immunizing cells.  HCSF acts on a  cell which is present  in bone 
marrow, spleen, blood, and peritoneal cells but absent in thymus or lymph node cells. 
This target cell  is  found in the less-dense  layer of a  discontinuous  Ficoll-gradient  of 
bone marrow cells.  HCSF is heat  stable,  destroyed by trypsin  treatment,  and  has  a 
molecular weight between 50,000 and  100,000. It acts on its target cells by increasing 
histidine decarboxylase activity. 
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